title: Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
authors.forename: Elisa
authors.initials: E
authors.lastname: Zonta
authors.forename: Vanna
authors.initials: V
authors.lastname: Chiarion
authors.forename: Haik
authors.initials: H
authors.lastname: Zarian
authors.forename: Andrea
authors.initials: A
authors.lastname: Peserico
authors.forename: Mauro
authors.initials: M
authors.lastname: Alaibac
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012867:Skin / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins